$720 Million is the total value of First Light Asset Management, LLC's 73 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 26.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARRY | Sell | ARRAY BIOPHARMA INC | $56,177,000 | +3.7% | 1,212,545 | -45.4% | 7.80% | +10.8% |
| NEO | Sell | NEOGENOMICS INC | $29,083,000 | -11.4% | 1,325,582 | -17.4% | 4.04% | -5.3% |
| OMCL | Sell | OMNICELL INC | $28,516,000 | -32.4% | 331,462 | -36.5% | 3.96% | -27.8% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $25,396,000 | -1.0% | 713,769 | -6.5% | 3.53% | +5.8% |
| IONS | Sell | IONIS PHARMACEUTICALS INC | $21,025,000 | -57.6% | 327,132 | -46.5% | 2.92% | -54.7% |
| XNCR | Sell | XENCOR INC | $20,438,000 | +28.7% | 499,344 | -2.3% | 2.84% | +37.5% |
| HRTX | Sell | HERON THERAPEUTICS INC | $20,425,000 | -24.9% | 1,098,723 | -1.3% | 2.84% | -19.8% |
| HALO | Sell | HALOZYME THERAPEUTICS INC | $18,345,000 | -22.6% | 1,067,813 | -27.4% | 2.55% | -17.3% |
| IMMU | Sell | IMMUNOMEDICS INC | $16,970,000 | -37.1% | 1,223,483 | -12.9% | 2.36% | -32.8% |
| VCYT | Sell | VERACYTE INC | $16,795,000 | -13.1% | 589,099 | -23.7% | 2.33% | -7.2% |
| XENT | Sell | INTERSECT ENT INC | $15,224,000 | -34.3% | 668,893 | -7.1% | 2.11% | -29.7% |
| LGND | Sell | LIGAND PHARMACEUTICALS INC | $11,261,000 | -31.9% | 98,649 | -25.0% | 1.56% | -27.2% |
| TNDM | Sell | TANDEM DIABETES CARE INC | $8,831,000 | -48.1% | 136,865 | -48.9% | 1.23% | -44.5% |
| HBIO | Sell | HARVARD BIOSCIENCE INC | $1,176,000 | -96.1% | 588,148 | -91.7% | 0.16% | -95.9% |
| PKI | Exit | PERKINELMER INC | $0 | – | -2,245 | -100.0% | -0.03% | – |
| TFX | Exit | TELEFLEX INCORPORATED | $0 | – | -777 | -100.0% | -0.03% | – |
| Exit | INVESCO SMALLCAP HEALTH CARE ETFetf | $0 | – | -17,285 | -100.0% | -0.26% | – | |
| GMED | Exit | GLOBUS MEDICAL INC | $0 | – | -103,356 | -100.0% | -0.66% | – |
| DVAX | Exit | DYNAVAX TECHNOLOGIES CORP | $0 | – | -1,709,541 | -100.0% | -1.62% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ATRICURE INC | 40 | Q3 2023 | 9.7% |
| NEOGENOMICS INC | 40 | Q3 2023 | 10.6% |
| SANOFI-SYNTHELABO | 40 | Q3 2023 | 1.9% |
| JOHNSON & JOHNSON | 40 | Q3 2023 | 0.3% |
| PFIZER INC | 39 | Q2 2023 | 0.9% |
| BIOMARIN PHARMACEUTICAL INC | 36 | Q3 2023 | 1.6% |
| OMNICELL INC | 33 | Q3 2023 | 7.7% |
| QUIDEL CORP | 33 | Q4 2021 | 3.7% |
| NOVARTIS AG-SPONSORED ADR | 33 | Q3 2023 | 0.4% |
| MODEL N INC | 30 | Q3 2023 | 9.0% |
View First Light Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| REATA PHARMACEUTICALS INC | May 15, 2023 | 1,290,193 | 3.9% |
| Axogen, Inc. | February 03, 2023 | 1,942,270 | 4.6% |
| MODEL N, INC. | February 03, 2023 | 1,845,134 | 4.9% |
| MEI Pharma, Inc.Sold out | May 31, 2022 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | March 01, 2022 | 1,805,038 | 3.9% |
| Intersect ENT, Inc. | February 14, 2022 | 1,375,210 | 4.1% |
| SeaSpine Holdings Corp | February 14, 2022 | 6,847,707 | 18.8% |
| Oxford Immunotec Global PLCSold out | February 10, 2021 | 0 | 0.0% |
| ENDOLOGIX INC /DE/ | February 14, 2020 | 816,236 | 4.6% |
| Nuvectra CorpSold out | February 14, 2020 | 0 | 0.0% |
View First Light Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13D/A | 2024-04-09 |
| 4 | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
View First Light Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.